Chemical Peels and Rosacea: Why Irritation Risk Changes the Decision

Does irritation risk mean this peel is not now?

If you have diagnosed rosacea and a cosmetic clinic, med spa, or aesthetician offers you a chemical peel, the default, evidence-grounded clinical answer is not now. Chemical peels are formulated to induce controlled chemical destruction of the stratum corneum and underlying epidermal layers to stimulate wound healing and cellular turnover. In healthy, photodamaged skin, this controlled injury prompts orderly re-epithelialization. In a patient with rosacea, however, the epidermal barrier is already defective, cutaneous neurovascular tone is unstable, and the innate immune system is chronically sensitized. Applying a peel acid onto that terrain adds intended epidermal injury to a barrier that already stings and leaks.

This guide evaluates one specific patient decision: for a named peel offer—characterized by its active acid, stated depth, concentration, setting (clinical office versus at-home), and your current rosacea features—whether irritation risk marks the procedure as not now, whether the only researched peel class is a small-cohort in-office supramolecular salicylic acid (SSA) protocol restricted strictly to papulopustular disease that does not transfer to other acids or depths, or whether key clinical variables remain unknown. This analysis is a phenotype-and-depth evidence appraisal. It is not an alternative treatment ranking, not a resurfacing laser comparison, not an analysis of Baker-Gordon phenol cardiac arrhythmias, not an acne-scar cross-technique protocol, not a cosmetic AHA chemistry review, and not a recipe for self-treatment.

The fundamental divergence in rosacea management lies between clinical dermatological guidance and commercial aesthetic marketing. While commercial treatment menus routinely advertise chemical peels as 'clarifying facials' or 'redness-calming peels,' clinical practice guidelines established by the National Rosacea Society (NRS) Expert Committee and the American Academy of Dermatology (AAD) prioritize barrier repair, trigger avoidance, FDA-approved prescription topicals (such as azelaic acid, metronidazole, ivermectin, and encapsulated benzoyl peroxide), subantimicrobial oral doxycycline, and targeted vascular lasers (such as pulsed dye laser and KTP). Chemical peels do not appear as a recommended therapeutic row in the NRS clinical algorithms retrieved in September 2026.

Why a leaky barrier makes exfoliation a different decision

To understand why chemical peels pose a unique hazard in rosacea, one must examine the stratum corneum not as inert dead skin, but as an active neuro-immunological shield. In healthy skin, the stratum corneum functions as a 'brick-and-mortar' structure where terminally differentiated corneocytes are embedded in a hydrophobic, lipid-rich extracellular matrix composed of ceramides, cholesterol, and free fatty acids. In rosacea, this barrier is fundamentally compromised.

In a comprehensive clinical review on the skin barrier in rosacea published in Anais Brasileiros de Dermatologia (Addor, 2016; PMC4782648), investigators documented significantly increased transepidermal water loss (TEWL) across both major cutaneous subtypes: erythematotelangiectatic rosacea (ETR) and papulopustular rosacea (PPR). This elevated TEWL is evidence of a leaky barrier with reduced epidermal hydration. Addor also notes that epidermal inflammation and cathelicidin activity can disrupt lipid synthesis and stratum corneum formation, which helps explain burning, stinging, and poor tolerance of topical products.

This physiological deficit directly drives patient symptoms. Addor cited a benchmark National Rosacea Society survey of 1,023 patients in which 82% of respondents reported irritable skin characterized by burning, stinging, or painful sensations upon applying everyday cosmetic and skincare products. The survey identified exfoliating products, facial tonics, astringents, and traditional soaps as the primary triggers provoking acute cutaneous burning. When a barrier already stings from everyday cosmetics, a peel is still an exfoliant applied to that barrier.

Addor also cites evidence that TRPV1, the capsaicin-sensitive ion channel, is more highly expressed in rosacea and helps explain greater discomfort from chemically similar substances. That is a mechanism for sting, not a license to write a peel protocol. A peel remains, by design, a concentrated exfoliant on a barrier that already reports burning from milder products.

The American Academy of Dermatology's public guidance on preventing rosacea flare-ups reinforces this reality, advising patients to avoid all skincare products that burn, sting, itch, or cause scaling, and specifically instructing readers to eliminate astringents and toners. A chemical peel is, by its definitive biological mechanism, a concentrated chemical exfoliant. In skin with an intact barrier, the resulting desquamation stimulates epidermal renewal. In rosacea, it inflicts acute trauma on a tissue bed that lacks the lipid architecture and vascular stability to repair itself without escalating inflammation. For readers managing compromised skin, reviewing damaged skin barrier repair protocols highlights the extensive recovery time required to restore lipid lamellae before any procedure can even be evaluated.

What NRS and AAD actually list instead of peels

When patients inquire about chemical peels to address persistent redness, facial roughness, or stubborn breakouts, they are frequently seeking solutions for problems that dermatology manages through entirely different, evidence-graded therapeutic classes. Contemporary rosacea care is grounded in the phenotype-based consensus established by the National Rosacea Society Expert Committee (Gallo et al., JAAD 2018;78:148-155) and updated in its standard management guidelines (Thiboutot et al., JAAD 2020;82:1501-1510).

The phenotype framework discards broad, rigid subtype boxes and instead tailors clinical interventions directly to presenting cutaneous features:

• Persistent Centrofacial Erythema: Managed through daily non-chemical barrier care, identification and avoidance of environmental triggers, strict daily broad-spectrum mineral photoprotection (SPF 30+ with zinc oxide or titanium dioxide), topical alpha-2 adrenergic receptor agonists for temporary vasoconstriction (brimonidine tartrate 0.33% gel or oxymetazoline hydrochloride 1% cream), and vascular energy devices (pulsed dye laser, KTP laser, or intense pulsed light).

• Inflammatory Papules and Pustules: Addressed with FDA-approved topical anti-inflammatory agents including azelaic acid 15% (gel or foam), metronidazole 0.75% or 1% (cream, gel, or lotion), ivermectin 1% cream, and microencapsulated benzoyl peroxide 5% (Epsolay). In moderate-to-severe presentations, dermatologists prescribe oral anti-inflammatory antibiotics, specifically subantimicrobial-dose doxycycline (40 mg modified-release daily), which inhibits matrix metalloproteinases and inflammatory cytokines without exerting antimicrobial selective pressure or inducing bacterial resistance.

• Visible Telangiectasias: Individual branching vessels cannot be dissolved by topical creams or chemical acids; they require selective photothermolysis via vascular-specific lasers (595 nm pulsed dye laser, 532 nm KTP laser) or broadband light (IPL) to coagulate intravascular oxyhemoglobin while sparing the surrounding dermis.

• Phymatous Changes: Tissue hypertrophy and sebaceous hyperplasia, most commonly presenting as rhinophyma on the nasal pyramid, do not respond to chemical peels. Early non-fibrotic stages may be treated medically with oral isotretinoin, whereas advanced fibrotic thickening requires surgical debulking, electrosurgery, or fully ablative CO2 or Er:YAG laser resurfacing.

• Ocular Rosacea: Blepharitis, conjunctival injection, lid margin telangiectasias, and foreign body sensation require lid hygiene, artificial tears, oral doxycycline, or ophthalmic cyclosporine emulsion, with mandatory ophthalmologic co-management.

The evidentiary foundation for these options was rigorously examined in the Cochrane Systematic Review Interventions for rosacea (van Zuuren et al., 2015), which synthesized data across 106 randomized controlled trials involving 13,631 participants. The Cochrane authors established high-quality evidence for topical azelaic acid, topical ivermectin, brimonidine, and oral subantimicrobial-dose doxycycline and isotretinoin; moderate-quality evidence for topical metronidazole and oral tetracycline; and low-quality evidence for low-dose minocycline, laser and IPL, and ciclosporin ophthalmic emulsion for ocular disease. Chemical peels were not among those graded interventions. Absence from a 2015 review is not proof that every later peel trial is worthless; it shows peels were not on the high-quality rosacea-treatment rung. StatPearls lists rosacea among textbook peel indications, beside precautions such as active infection, open wounds, isotretinoin, peel-agent allergy, and caution in darker phototypes. A general indication list in a peel chapter is not NRS phenotype management and does not override the irritation-risk default for glycolic, medium, or deep peels. In the NRS treatment algorithms retrieved 19 September 2026, chemical peeling is not a listed therapeutic row. Recent isotretinoin is a peel precaution, not a reason to treat phymatous change with a peel; waiting-period evidence is in isotretinoin and aesthetic-procedure timing.

This absence is reinforced in patient-education guidance. In the October 20, 2022 National Rosacea Society clinical feature How to Reduce the Impact of Cosmetic Procedures on Rosacea, board-certified dermatologist Dr. Estee Williams specifically addressed chemical peeling, emphasizing that many peels utilize alpha-hydroxy acids (such as glycolic acid) that rosacea patients should avoid entirely. Dr. Williams noted that 'Chemical peels are generally a no-no because their exfoliative action causes redness and flaking, exactly the last thing rosacea patients need.' While the NRS greens-lights vascular lasers for telangiectasias and notes that facial neuromodulator injectables do not interfere with underlying vascular structure, chemical peeling remains an acknowledged irritant. Readers exploring validated therapies can reference the comprehensive rosacea treatment guide, our analysis of topical azelaic acid safety and protocols, and the clinical review of the best vascular lasers for rosacea erythema.

Peel depth is the injury class: superficial, medium, deep

A significant source of patient confusion is the generic word 'peel.' In aesthetic marketing, 'chemical peel' is often presented as a singular, uniform treatment. In clinical dermatology, however, chemical peels are strictly categorized by their histological depth of injury—the exact anatomical plane within the skin to which chemical destruction penetrates. The International Peeling Society (IPS) consensus classification (Lee, Wambier, Soon et al., JAAD 2019;81:313-324) delineates three distinct depth categories:

• Superficial Peels (Epidermal Depth): These formulations cause keratolysis or controlled injury limited to the epidermis. Common agents include glycolic acid, lactic acid, mandelic acid, salicylic acid (often 20% to 30%), and Jessner's solution. AAD and Mayo Clinic describe light-peel recovery on the order of 1 to 7 days, with redness, tightness, and flaking. NRS still treats glycolic/AHA peels as a general no in rosacea because that exfoliation causes redness and flaking on a sting-prone barrier. Mandelic-peel marketing that claims rosacea suitability did not have a comparable RCT in this research set.

• Medium-Depth Peels (Papillary Dermal Depth): These agents reach the papillary dermis. Lee 2019 lists common medium-depth combinations such as Jessner's plus 35% TCA or 70% glycolic acid plus 35% TCA; TCA 10% to 35% can also be used as a superficial peel, so a concentration label alone does not prove medium depth. AAD FAQs state that after a medium peel healing is 7 to 14 days, with redness, swelling that can worsen for 48 hours, and possible blisters and crusting; persistent redness may last for months. Mayo Clinic notes that after any depth the skin is red, tight, irritated, or swollen, and that deeper peels take longer with possible months of redness and pigment change. International Peeling Society guidance (Lee 2019) does not recommend medium-depth peels for Fitzpatrick phototypes IV and above because of PIH risk. That injury class is the opposite of treating rosacea skin gently, so the mark is not now.

• Deep Peels (Reticular Dermal Depth): Deep peeling reaches the reticular dermis, classically with Baker-Gordon phenol-croton oil formulas. Chemical peels work by keratolysis and protein coagulation, not liquefactive necrosis. Phenol has documented cardiotoxicity risk; AAD FAQs state a person can have only one deep peel, with 2 to 3 weeks of recuperation at home, and that persistent redness may last for months; medium and deep peels can lighten skin color. Lee 2019 separately flags hypopigmentation and cardiotoxicity for 88% phenol. This page does not rewrite the Baker-Gordon monitoring argument; the candidacy mark in rosacea is not now.

Depth dismantles the idea that any treatment called a peel can smooth rosacea away. Medium and deep peels reach dermis to create a wound-healing cascade. On rosacea skin, that intended injury is the opposite of the NRS instruction to treat the barrier gently, and redness after a medium or deep peel can last months. For patients comparing resurfacing modalities, our analysis of chemical peeling versus laser resurfacing and the clinical investigation of deep phenol chemical peel cardiac and recovery risks detail these histological boundaries.

Evidence-and-limit table: offer, features, grade, mark

To evaluate whether a specific chemical peel offer should be considered, deferred, or rejected, readers must assess four intersecting clinical variables: the exact chemical agent and its intended depth, your presenting rosacea phenotype, the strength of supporting peer-reviewed evidence, and the material barrier-disruption risk. The following evidence-and-limit table synthesizes current guideline recommendations and clinical trial findings into an objective candidacy matrix:

To visualize how these clinical variables interact during an aesthetic consultation, the following decision flow illustrates the mandatory screening steps required before evaluating a chemical peel:

flowchart TD
    Start["Rosacea Patient Offered Chemical Peel"] --> Q1{"Is it an at-home or\nunsupervised kit?"}
    Q1 -- Yes --> StopHome["NOT NOW\nFDA 2024 Warning: Severe Burns & Scars"]
    Q1 -- No (In-Office) --> Q2{"Is skin actively stinging,\nflaring, or barrier impaired?"}
    Q2 -- Yes --> StopFlare["NOT NOW\nPrioritize Barrier Repair & Prescribed Topicals"]
    Q2 -- No (Stable) --> Q3{"What is the intended\npeel depth?"}
    Q3 -- "Medium-depth (TCA 30-35% or Jessner plus TCA) or phenol" --> StopDepth["NOT NOW\nDermal injury class; redness can last months"]
    Q3 -- "Superficial (Epidermal)" --> Q4{"What is the active\nacid and phenotype?"}
    Q4 -- "Glycolic / AHA in ETR or Redness" --> StopAHA["NOT NOW\nNRS Warning: Exfoliation Induces Flare"]
    Q4 -- "30% SSA in Papulopustular Rosacea" --> CheckSSA["RESEARCHED CONTEXT ONLY\nChina Trials Show PPR Benefit;\nFDA Medicines Remain First-Line"]
    Q4 -- "Unspecified Acid or Depth" --> StopUnknown["UNKNOWN\nObtain Written Consent Specifics Before Proceeding"]

What the SSA papers do and do not license

When clinics, med spas, or skincare brands assert that chemical peels are clinically proven to treat rosacea, they are often referencing a small cluster of peer-reviewed studies investigating supramolecular salicylic acid (SSA) in mainland China. Because these studies are frequently misquoted or stripped of their experimental context, examining their exact methodologies and limitations is essential.

To date, three primary publications form the scientific backbone of the SSA literature in rosacea:

• Wang L et al., 2020 (Experimental and Therapeutic Medicine; PMC7388548): This was a retrospective analysis of 19 patients diagnosed with papulopustular rosacea. The clinical protocol combined in-office 30% SSA peels administered twice monthly for 12 weeks with concurrent oral minocycline 50 mg twice daily. While investigator-assessed severity scores fell from 3.32±0.6 to 0.89±0.7, the study had profound structural limitations: it lacked a control group, enrolled only 19 participants, was retrospective, and evaluated combination therapy. It is impossible to separate the therapeutic impact of the chemical peel from the well-established anti-inflammatory efficacy of systemic minocycline.

• Xu et al., 2022 (Indian Journal of Dermatology; PMC9971792): This randomized controlled trial enrolled 60 patients with papulopustular rosacea, with 58 completing the 9-week protocol. Critically, both arms received topical 0.75% metronidazole gel twice daily. The experimental arm added three in-office 30% SSA peels spaced three weeks apart. At week 9, the erythema index was lower in the SSA add-on arm (10.29±1.34 versus 12.50±1.00 in the metronidazole-only arm). Transepidermal water loss (TEWL) was not significantly different between the two groups. Aesthetic marketing that cites Xu et al. as proof that 'salicylic peels alone cure rosacea' misrepresents the data: SSA was an adjunct to standard prescription topical metronidazole, not a monotherapy.

• Wang Z et al., February 2025 (Journal of Cosmetic Dermatology; PMC11836920; PMID 39968706): This investigation represents the only published randomized, vehicle/placebo-controlled trial of 30% SSA in papulopustular rosacea. Thirty-four patients were randomized, with 31 completers evaluated in primary efficacy tables (16 in the SSA arm, 15 in the control arm). The application protocol involved applying 30% SSA paste, massaging it with repeated water brushing for 10 to 15 minutes, and following with a cold polymer compress. The authors reported a treatment efficiency of 68.75% in the experimental arm (1 complete clearance, 10 significant improvements, 5 mild improvements, 0 non-responders) compared to 0% in the placebo group. Mean inflammatory lesion counts decreased from 38.06±10.40 to 13.19±7.30 in the SSA arm versus 36.53±9.96 to 29.93±7.69 in the control arm (p<0.01). Stratum corneum hydration improved and erythema scores declined without a statistically significant difference in TEWL between groups.

While the 2025 Wang et al. trial provides intriguing pilot evidence that a specific salicylic acid formulation can reduce papules and pustules without destabilizing barrier metrics, converting these findings into a universal endorsement of chemical peeling is scientifically invalid. The boundaries of this evidence base are strict and non-negotiable:

• Proprietary Supramolecular Vehicle: The studies evaluated a patented supramolecular salicylic acid formulation (Broda, Shanghai Ruijie) in which salicylic acid is complexed with amphiphilic poloxamer 407 polymers in a water-soluble matrix. In this supramolecular state, salicylic acid is solubilized without organic solvents, slowly releasing active acid onto the skin. Standard in-office salicylic acid peels used in North America and Europe are typically formulated at 20% to 30% in an ethanol or hydroethanolic base. Alcohol evaporates rapidly upon application, causing extreme cutaneous desiccation, barrier lipid extraction, and intense alcohol-induced stinging that can provoke a severe rosacea flare. The tolerability of aqueous SSA cannot be claimed for generic alcohol-based salicylic acid peels.

• Phenotype Specificity: All three trials enrolled exclusively patients with papulopustular rosacea (PPR). Salicylic acid is a lipophilic beta-hydroxy acid that concentrates within the pilosebaceous unit, exerting comedolytic, keratolytic, and mild anti-inflammatory effects around follicular pustules. These trials enrolled zero patients with erythematotelangiectatic rosacea (ETR) alone, zero patients with ocular rosacea, and zero patients with phymatous rosacea. SSA does not coagulate blood vessels or eliminate telangiectasias.

• Sample Size and Geographical Constraints: The entire published randomized controlled trial evidence base for SSA monotherapy in rosacea rests on 31 completers in a single academic medical center in China. There are no multicenter, large-scale (Phase III), diverse-cohort trials validating these outcomes.

• Zero Support for Other Chemical Acids: Positive data for a 30% water-soluble salicylic acid formulation provide absolutely zero clinical validation for glycolic acid, lactic acid, mandelic acid, trichloroacetic acid (TCA), or phenol peels. Each chemical agent possesses distinct pKa values, penetration mechanisms, and tissue-coagulation profiles.

• Unpublished Clinical Registry Trials: A registered UT Southwestern pilot (ClinicalTrials.gov NCT04889703) planned to compare 15% TCA and 30% salicylic acid peels, two treatments four weeks apart, in about 20 people with rosacea. This research found no published results to cite as efficacy. Registration is not evidence of benefit.

At-home kits and high-acid peelers: FDA's 2024 stop

The proliferation of direct-to-consumer chemical peels on online marketplaces, e-commerce platforms, and social media represents one of the most alarming safety challenges in contemporary aesthetic skincare. On July 30, 2024, the U.S. Food and Drug Administration issued an explicit, high-priority consumer warning: FDA warns against purchasing or using chemical peel skin products without professional supervision.

The FDA's regulatory statement establishes critical facts that every patient must understand:

• No chemical peel product is FDA-approved: FDA stated that the agency has not approved any chemical peel products. Consumers should only consider chemical peels under a dermatologist or licensed and trained practitioner.

• Extreme Acid Concentrations: The FDA documented that consumer peel products sold online without prescription contain dangerously high concentrations of caustic chemicals intended solely for specialized medical use. Named examples identified in FDA investigations included trichloroacetic acid (TCA) up to 100%, glycolic acid up to 70%, salicylic acid up to 80%, and lactic acid up to 90%.

• Severe Material Injuries: The agency warned that applying high-concentration chemical peels without professional supervision routinely causes severe chemical burns, excruciating pain, profound facial swelling, secondary bacterial and fungal infections, permanent skin discoloration (hyperpigmentation and hypopigmentation), and severe, disfiguring scars that require emergency department treatment and reconstructive surgical intervention.

AAD's public peel overview repeats the FDA advice: buy and use a chemical peel only under the supervision of a licensed, trained provider such as a dermatologist. FDA's own wording is a dermatologist or licensed and trained practitioner—not a claim that every peel requires a named supervising physician on the consent, and not FDA approval of any peel product.

This warning sits beside older FDA AHA surveillance. Between 1992 and February 2004 the agency logged 114 dermatologic adverse-event reports for AHA-containing products, including burning, dermatitis, swelling, pigmentary change, blisters, peeling, and chemical burns, with more serious reactions clustered in skin peelers. Volunteer studies found that after four weeks of AHA application, UV-related skin reddening sensitivity rose about 18% and sensitivity to UV-induced cellular damage roughly doubled; that extra sensitivity reversed, with no significant difference one week after stopping. The same FDA page states that the studies did not appear to involve dramatic increases in UV-induced DNA damage in the skin.

On rosacea skin, an unsupervised high-concentration kit is still a hard no, independent of subtype. FDA's 2024 alert already names severe burns, pigment change, infection, and disfiguring scars from high-acid home products. A leaky barrier does not make those kits safer. At-home high-acid peelers are not a rosacea treatment class.

Skin of color: PIH and missed erythema stay unknown unless examined

Evaluating chemical peeling in patients with rosacea who have darker skin tones (Fitzpatrick phototypes IV, V, and VI) introduces an additional layer of biological risk and diagnostic complexity. In aesthetic medicine, skin-of-color safety is not a trivial footnote; it is a fundamental determinant of procedural candidacy.

The primary material hazard of chemical peeling in Fitzpatrick phototypes IV–VI is post-inflammatory hyperpigmentation (PIH). AAD FAQs state that people with skin of color can have a peel but should see a dermatologist with expertise treating darker skin, or permanent pigment problems can occur. Lee 2019 states medium-depth peels are not recommended for Fitzpatrick phototypes IV and above because of PIH risk. This page does not name a safest acid for rosacea in dark skin; that job belongs to the dedicated dark-skin peel article.

This physiological vulnerability is compounded by diagnostic disparities. In Fitzpatrick phototypes I to III, rosacea is easily recognized by bright red facial flushing, persistent pink erythema, and visible telangiectasias. In Fitzpatrick phototypes V and VI, however, facial erythema does not appear bright red. As detailed in clinical literature and National Rosacea Society diagnostic reviews:

• Atypical Chromatic Presentation: Persistent erythema in deeper skin tones frequently appears violaceous, dusky, hyperpigmented, or dark brown. The abundance of epidermal eumelanin absorbs and scatters red light, visually masking underlying vascular dilation.

• Concealed Telangiectasias: Superficial branching blood vessels are often completely obscured by melanin pigment, preventing visual identification during standard clinic inspection.

• Subjective Symptom Dominance: Patients with rosacea and darker skin tones often present with intense subjective symptoms—severe facial burning, stinging, tightness, and heat—without dramatic visible redness.

Because of these diagnostic nuances, rosacea in skin of color is frequently misdiagnosed as acne vulgaris, seborrheic dermatitis, or melasma. If bumps and dusky patches are treated as acne or pigment with an aggressive peel, the reader is left with intended epidermal injury plus PIH risk on a missed inflammatory diagnosis. That is why the irritation default is stricter here, not a named safest acid.

The SSA trials cannot be generalized into a Fitzpatrick IV–VI peel protocol. Wang 2020, Xu 2022, and Wang 2025 did not report Fitzpatrick-stratified PIH analyses. In the International Peeling Society review (Lee et al., JAAD 2019), expert dermatologists explicitly advise that medium-depth peels are not recommended for Fitzpatrick phototypes ≥IV because of post-inflammatory hyperpigmentation risk. StatPearls separately lists caution in darker phototypes and notes that people with darker skin and a history of hypertrophic scarring sit at higher complication risk; that is a general peel precaution, not a rosacea-specific PIH rate.

AAD FAQs say people with skin of color can have a peel but should see a dermatologist who has expertise using chemical peels on darker skin; without that expertise, permanent pigment problems can occur. Until phenotype, flare status, and PIH risk are examined, the candidacy mark stays unknown and elevated rather than assumed low. Patients seeking dedicated guidance on pigmentary risks should consult our evidence reviews on chemical peels in skin of color and the diagnostic evaluation of rosacea in darker skin tones.

Sources

• National Rosacea Society. How to Reduce the Impact of Cosmetic Procedures on Rosacea. Expert interview with Dr. Estee Williams, October 20, 2022. Identifies glycolic/AHA chemical peels as a general 'no-no' due to redness and flaking.

• National Rosacea Society. Rosacea Treatment Algorithms. Clinical management algorithms organized by phenotype based on the 2019 Expert Committee update. Retrieved September 19, 2026. Confirms absence of chemical peels as a recognized treatment row.

• National Rosacea Society. Why Is There Acid in My Face Wash?. Patient education primer on topical skincare acids, June 17, 2019. Details irritation risks of glycolic and salicylic acids and therapeutic role of azelaic acid.

• Thiboutot D, Anderson R, Borelli E, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. Journal of the American Academy of Dermatology. 2020;82(6):1501-1510. Consensus phenotype management guidelines.

• Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. Journal of the American Academy of Dermatology. 2018;78(1):148-155. Landmark shift from subtypes to clinical phenotypes.

• American Academy of Dermatology. Rosacea: Diagnosis and Treatment. Public clinical guidance detailing FDA-approved prescription topicals, oral antibiotics, and vascular lasers for rosacea management.

• American Academy of Dermatology. How to Prevent Rosacea Flare-Ups. Guidance on avoiding products that cause burning, stinging, or peeling, and stopping toners and astringents.

• American Academy of Dermatology. Chemical Peels: Overview. Overview of clinical peel indications (acne, discoloration, photoaging), procedural setting requirements, and the FDA consumer warning.

• American Academy of Dermatology. Chemical Peels: FAQs. Technical summary of peel healing times (7–14 days for medium peels), deep peel restrictions, and skin-of-color dyschromia precautions.

• U.S. Food and Drug Administration. FDA Warns Against Purchasing or Using Chemical Peel Skin Products Without Professional Supervision. FDA Drug Safety Alert, July 30, 2024. Warns against unapproved online high-concentration TCA, glycolic, salicylic, and lactic acid peel kits causing severe burns and permanent scarring.

• U.S. Food and Drug Administration. Alpha Hydroxy Acids in Cosmetics. Regulatory analysis of 114 dermatologic adverse event reports, serious injuries in chemical peelers, and clinical findings on UV photosensitivity.

• Addor FAS. Skin barrier in rosacea. Anais Brasileiros de Dermatologia. 2016;91(1):59-63. Reviews increased TEWL in ETR and PPR, and documents the 82% rate of cosmetic-induced stinging and burning.

• Lee KC, Wambier CG, Soon SL, et al. Basic chemical peeling: Superficial and medium-depth peels. Journal of the American Academy of Dermatology. 2019;81(2):313-324. International Peeling Society consensus on anatomical depth, healing timelines, and Fitzpatrick IV–VI precautions.

• Wang L, et al. Retrospective analysis of 19 papulopustular rosacea cases treated with oral minocycline and supramolecular salicylic acid 30% chemical peels. Experimental and Therapeutic Medicine. 2020. Retrospective combination study with oral minocycline (PMC7388548).

• Xu L, Yao B, Xu T, Huang H. Assessment of the Efficacy and Safety of 30% Supramolecular Salicylic Acid Peeling for Papulopustular Rosacea Treatment. Indian Journal of Dermatology. 2022;67(6):670-675. Randomized trial of SSA add-on therapy alongside topical metronidazole 0.75%.

• Wang Z, et al. 30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea. Journal of Cosmetic Dermatology. 2025;24(2):e16920. Randomized, placebo-controlled trial of Broda SSA paste in 31 completing patients.

• van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea. Cochrane Database of Systematic Reviews. 2015;4:CD003262. Systematic review of 106 RCTs evaluating evidence grades for rosacea therapies.

• Samargandy S, Raggio BS. Chemical Peels for Skin Resurfacing. StatPearls Publishing / NCBI Bookshelf (NBK547752). Textbook peel review that lists rosacea among indications and states precautions including isotretinoin and darker phototypes.

• Mayo Clinic. Chemical Peel: Overview, Risks, and Expectations. Clinical procedure guide detailing light, medium, and deep peeling recovery milestones, infection risks, and dyschromia hazards.

• UT Southwestern Medical Center. A Pilot Study Testing the Effects of Chemical Peels in Patients With Rosacea. ClinicalTrials.gov Identifier NCT04889703. Registered pilot comparing 15% TCA and 30% salicylic acid; zero published results as of September 2026.